Sunny Pharmtech Issues Recall of Cyclophosphamide Injection Due to Contamination
Sunny Pharmtech is recalling Cyclophosphamide for Injection due to contamination with particulate matter identified as steel.
Company
competing pharma companies
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The recall of Cyclophosphamide Injection due to contamination poses significant risks to patient safety and treatment continuity in oncology. This situation may disrupt supply chains and create opportunities for competitors to capture market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for updates on the recall process and any reported adverse events related to the contaminated lots.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.